一分钟看懂
这是一项关于胆道癌的III 期研究，登记的药物或干预包括Zanidatamab；Cisplatin；Gemcitabine；Pembrolizumab；Durvalumab，当前状态为招募中。登记地点显示中国合肥、北京、兰州、哈尔滨等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Zanidatamab；Cisplatin；Gemcitabine；Pembrolizumab；Durvalumab · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of USTC(Anhui Provincial Hospital) · 合肥
- Beijing Cancer Hospital · 北京
- The First Hospital of Lanzhou University · 兰州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Hunan Provincial People's Hospital · 长沙
- Jilin Cancer Hospital · 长春
- Shandong Provincial Third Hospital · 济南
- Sichuan Cancer Hospital · 成都
- West China Hospital Sichuan University · 成都
- Zhongshan Hospital Fudan University · 上海
公开的入选条件
- 1. Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC).
- 2. Locally advanced unresectable or metastatic BTC and not eligible for curative resection, transplantation, or ablative therapies.
- 3. Received no more than 2 cycles of systemic therapy which is limited to Cisplatin and Gemcitabine (CisGem) with or without a PD-1/L1 inhibitor (physician's choice of durvalumab or pembrolizumab, where approved under local regulations) for advanced unresectab
- 4. HER2-positive disease (defined as IHC 3+; or IHC 2+/ ISH+) by IHC and in situ Hybridization (ISH) assay (in participants with IHC 2+ tumors) at a central laboratory on new biopsy tissue or archival tissue from the most recent biopsy.
- 5. Assessable (measurable or non-measurable) disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), per investigator assessment.
- 6. Male or female ≥ 18 years or age (or the legal age of adulthood per country-specific regulations).
- 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- 8. Adequate organ function
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06282575；登记信息更新于 2026-09-14。